获得性血友病A中抗艾美赛珠单抗抗体的综合评估:详细病例研究与方法学评价
本文报告首例获得性血友病A(AHA)患者在接受艾美赛珠单抗治疗第10周起疗效下降后,检测到抗艾美赛珠单抗抗体。研究建立了区分Ig亚类和IgG亚型的抗体分析方法,并发现该抗体无中和活性且未加速艾美赛珠单抗清除。
要点
- 首例AHA患者中检测到抗艾美赛珠单抗抗体,治疗第10周起疗效下降。
- 第16周至第29周血浆中检出抗艾美赛珠单抗IgG抗体,包括IgG1和IgG2亚类。
- 抗艾美赛珠单抗抗体无中和活性,且未观察到艾美赛珠单抗清除加速。
核心结论
- 本研究首次报告获得性血友病A患者中抗艾美赛珠单抗抗体的发生,提示需监测工具以优化临床使用。
研究设计与样本
- 对一例获得性血友病A患者进行详细病例研究,患者自治疗第10周起艾美赛珠单抗疗效下降;建立抗艾美赛珠单抗抗体分析方法,区分免疫球蛋白亚类和IgG亚型,并用改良凝血试验评估中和活性。
主要发现
- 基于Luminex的检测方法证实存在抗艾美赛珠单抗抗体,竞争分析进一步确认。
- 在患者血浆中第16周至第29周检测到抗艾美赛珠单抗IgG抗体,鉴定出IgG1和IgG2亚类。
- 纵向分析显示针对艾美赛珠单抗和凝血因子VIII的IgG同种型抗体。
- 改良Bethesda试验证实抗艾美赛珠单抗抗体无抑制活性,且患者血浆样本中未观察到艾美赛珠单抗清除加速。
临床怎么用
- 作者认为该研究提示需要监测工具以全面评估抗药物抗体,有助于个体化治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acquired hemophilia A (AHA) is a rare and severe bleeding disorder characterized by autoantibodies inhibiting coagulation factor (F)VIII. Current treatment of AHA involves bypassing agents or FVIII replacement therapy, yet their efficacy is limited in cases of high inhibitor titers. Emicizumab, a humanized bispecific monoclonal antibody, has shown promising hemostatic effectiveness in persons with congenital hemophilia A (HA) and AHA, but a minority of patients developed anti-drug antibodies (ADAs), compromising its efficacy. OBJECTIVES: This study aims to characterize the development and impact of anti-emicizumab antibodies in a patient with acquired hemophilia A (AHA) who experienced reduced efficacy of emicizumab treatment. METHODS: We present a comprehensive characterization of anti-emicizumab antibodies in a patient with AHA experiencing diminished emicizumab efficacy from week 10 of treatment. We developed a method for analysis of anti-emicizumab antibodies, distinguishing immunoglobulin (Ig) subclasses and IgG subtype profiling. ADAs' neutralizing activity was evaluated using a modified clotting assay. RESULTS: The Luminex-based assay demonstrated the presence of anti-emicizumab antibodies, confirmed through competitive analysis. We detected anti-emicizumab IgG antibodies in the patient's plasma between week 16 and 29. IgG1 and IgG2 subclasses were identified. Longitudinal analysis showed IgG isotype antibodies against both emicizumab and FVIII. Anti-emicizumab antibodies exhibited noninhibitory activity, confirmed by a modified Bethesda assay. Moreover, no accelerated clearance of emicizumab was observed in plasma samples from the patient. CONCLUSION: This study presents the first documented case of anti-emicizumab antibodies in AHA. Our study provides insights into ADA development against emicizumab, emphasizing the need for monitoring tools. The developed method enables comprehensive evaluation of ADAs, aiding in personalized treatment strategies. These findings contribute to understanding emicizumab's immunogenicity profile in AHA, facilitating its optimized clinical use.
引用
- Pezeshkpoor B, Sereda N, Becker-Gotot J, et al. Comprehensive evaluation of anti-emicizumab antibodies in acquired hemophilia A: a detailed case study and methodological evaluation. J Thromb Haemost. 2024. PMID: 39401737. doi:10.1016/j.jtha.2024.10.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。